2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street

Core Insights - The biotech industry is highlighted as a promising sector for future investment opportunities, particularly due to its innovative approaches to treating diseases [2][3]. Group 1: CRISPR Therapeutics - CRISPR Therapeutics achieved a significant milestone in 2023 with the approval of its first gene editing treatment, Casgevy, for blood disorders, marking the first approval of a CRISPR-based therapy [4]. - The gene editing technique utilized by CRISPR Therapeutics repairs genes responsible for diseases, acting as a functional cure, which positions it as a transformative technology in the healthcare sector [5]. - In Q4, Casgevy generated $54 million in revenue, contributing to a total of $116 million for the full year, indicating strong market potential [5]. - The company has over $1.9 billion in cash, which supports ongoing development and clinical trials for various disease indications, with expected updates on zugo-cel and CTX310 [6]. - Wall Street anticipates a 58% increase in the stock price over the next 12 months, suggesting a favorable investment opportunity [7]. Group 2: Viking Therapeutics - Viking Therapeutics is in late-stage clinical trials for its obesity drug candidate, VK2735, which is being developed in both injectable and oral formats [8]. - The injectable format is currently in a phase 3 trial, while the oral format is expected to enter phase 3 in Q3 of the year, indicating progress towards commercialization [8].